שווי פעילות לרווח לפני ריבית, מסים ופחת aditxt.com (ADTX)

Aditxt is fighting a tough battle for market position, attempting to balance the launch of immunotherapy with a heavy debt burden. The linear price action on the chart, where the EV/EBITDA ratio stands at 0.00, links these challenges to expansion through the acquisition of fintech and biotech assets to create product synergies. Meanwhile, the business relies on sustained interest in personalized medicine, which mitigates its moderate dependence on economic cycles.

Aditxt (ADTX) maintains its market share through complex certifications and unique patents in the field of immunity monitoring. The EV/EBITDA metric compares the total enterprise value, including debt, to operating profit, measuring the company's ability to service its obligations using core income. Investors should assess the asset's resilience to shocks by analyzing the volatility of the current valuation based on the EV/EBITDA multiple.